March 1989
Volume 30, Issue 3
Free
Articles  |   March 1989
Synergistic antiherpes virus activity of acyclovir and interferon in human corneal stromal cells.
Author Affiliations
  • J L Taylor
    Department of Microbiology, Medical College of Wisconsin, Milwaukee 53226.
  • M S Casey
    Department of Microbiology, Medical College of Wisconsin, Milwaukee 53226.
  • W J O'Brien
    Department of Microbiology, Medical College of Wisconsin, Milwaukee 53226.
Investigative Ophthalmology & Visual Science March 1989, Vol.30, 365-370. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J L Taylor, M S Casey, W J O'Brien; Synergistic antiherpes virus activity of acyclovir and interferon in human corneal stromal cells.. Invest. Ophthalmol. Vis. Sci. 1989;30(3):365-370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Synergistic anti-herpes simplex virus type 1 (HSV-1) activity between acyclovir (ACV) and recombinant human interferon alpha A2 (IFN) was detected in cell cultures derived from human corneas. This activity was demonstrated when cells were infected at high multipicities of infection (5 pfu/cell) in both cytopathic effect reduction and yield reduction assays as well as in plaque reduction assays at low multiplicities. The synergistic effects occurred over a 30-fold range of concentrations of IFN (6-200 IU/ml) and ACV (0.15-5 microM) at various ratios of the drugs. The augmentation of antiviral activity was greatest when cells were treated with IFN prior to infection and ACV following infection. The addition of IFN after infection, with simultaneous ACV treatment, also resulted in enhanced anti-HSV-1 activity. The combination of IFN with ACV did not increase the cytotoxicity of ACV. The synergistic antiviral activity in corneal cells may account for the previously reported enhanced efficacy of combined treatment with IFNs and nucleoside analogs for therapy of herpetic keratitis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×